Back to top
more

GT Biopharma (GTBP)

(Delayed Data from NSDQ)

$3.35 USD

3.35
10,376

-0.41 (-10.84%)

Updated Apr 26, 2024 03:13 PM ET

After-Market: $3.21 -0.14 (-4.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

GT Biopharma, Inc. (GTBP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now

GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

All You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to Buy

GT Biopharma, Inc. (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Has Albireo Pharma (ALBO) Outpaced Other Medical Stocks This Year?

Here is how Albireo Pharma (ALBO) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?

Here is how Aclaris Therapeutics (ACRS) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

Has Geron (GERN) Outpaced Other Medical Stocks This Year?

Here is how Geron (GERN) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

Has Ensign Group (ENSG) Outpaced Other Medical Stocks This Year?

Here is how Ensign Group (ENSG) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

OXIS International Inc. (GTBP) Loses 32.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for OXIS International Inc. (GTBP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

OXIS International Inc. (GTBP) Moves to Buy: Rationale Behind the Upgrade

OXIS International Inc. (GTBP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

OXIS International Inc. (GTBP) Gains As Market Dips: What You Should Know

OXIS International Inc. (GTBP) closed the most recent trading day at $12.51, moving +1.54% from the previous trading session.

GT Biopharma (GTBP) to Report Q1 Earnings: What to Expect?

GT Biopharma (GTBP) is expected to provide updates on its pipeline development when it reports first-quarter 2021 result.

OXIS International Inc. (GTBP) Gains As Market Dips: What You Should Know

In the latest trading session, OXIS International Inc. (GTBP) closed at $11.74, marking a +0.34% move from the previous day.

OXIS International Inc. (GTBP) Gains But Lags Market: What You Should Know

In the latest trading session, OXIS International Inc. (GTBP) closed at $9.64, marking a +0.63% move from the previous day.